Literature DB >> 16127073

Multiparametric assay to screen and dissect the mode of action of anti-human immunodeficiency virus envelope drugs.

Julià Blanco1, Imma Clotet-Codina, Berta Bosch, Mercedes Armand-Ugón, Bonaventura Clotet, José A Esté.   

Abstract

A flow cytometry-based assay was used to simultaneously quantify X4 and R5 human immunodeficiency virus (HIV) envelope-mediated cell-to-cell viral transfer, cell death, and cell-to-cell fusion. In this assay, different anti-HIV envelope drugs showed characteristic inhibitory profiles for each measured parameter, allowing for the rapid identification of the mode of action of active compounds.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16127073      PMCID： PMC1195414          DOI： 10.1128/AAC.49.9.3926-3929.2005

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  24 in total

1.  Automatic quantitation of HIV-1 mediated cell-to-cell fusion with a digital image analysis system (DIAS): application for rapid screening of HIV-1 fusion inhibitors.

Authors:  Hong Lu; Qian Zhao; Zhikai Xu; Shibo Jiang
Journal:  J Virol Methods       Date:  2003-02       Impact factor: 2.014

Review 2.  HIV-1 entry and its inhibition.

Authors:  T C Pierson; R W Doms
Journal:  Curr Top Microbiol Immunol       Date:  2003       Impact factor: 4.291

3.  SCH-C (SCH 351125), an orally bioavailable, small molecule antagonist of the chemokine receptor CCR5, is a potent inhibitor of HIV-1 infection in vitro and in vivo.

Authors:  J M Strizki; S Xu; N E Wagner; L Wojcik; J Liu; Y Hou; M Endres; A Palani; S Shapiro; J W Clader; W J Greenlee; J R Tagat; S McCombie; K Cox; A B Fawzi; C C Chou; C Pugliese-Sivo; L Davies; M E Moreno; D D Ho; A Trkola; C A Stoddart; J P Moore; G R Reyes; B M Baroudy
Journal:  Proc Natl Acad Sci U S A       Date:  2001-10-16       Impact factor: 11.205

4.  Cell-surface-expressed HIV-1 envelope induces the death of CD4 T cells during GP41-mediated hemifusion-like events.

Authors:  Julià Blanco; Jordi Barretina; Karine F Ferri; Etienne Jacotot; Arantxa Gutiérrez; Mercedes Armand-Ugón; Cecilia Cabrera; Guido Kroemer; Bonaventura Clotet; José A Esté
Journal:  Virology       Date:  2003-01-20       Impact factor: 3.616

5.  Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia.

Authors:  Adriano Lazzarin; Bonaventura Clotet; David Cooper; Jacques Reynes; Keikawus Arastéh; Mark Nelson; Christine Katlama; Hans-Jürgen Stellbrink; Jean-François Delfraissy; Joep Lange; Les Huson; Ralph DeMasi; Cynthia Wat; John Delehanty; Claude Drobnes; Miklos Salgo
Journal:  N Engl J Med       Date:  2003-05-29       Impact factor: 91.245

6.  HIV-1 resistance to the gp41-dependent fusion inhibitor C-34.

Authors:  Mercedes Armand-Ugón; Arantxa Gutiérrez; Bonaventura Clotet; José A Esté
Journal:  Antiviral Res       Date:  2003-07       Impact factor: 5.970

Review 7.  Virus entry as a target for anti-HIV intervention.

Authors:  José A Esté
Journal:  Curr Med Chem       Date:  2003-09       Impact factor: 4.530

Review 8.  The HIV Env-mediated fusion reaction.

Authors:  Stephen A Gallo; Catherine M Finnegan; Mathias Viard; Yossef Raviv; Antony Dimitrov; Satinder S Rawat; Anu Puri; Stewart Durell; Robert Blumenthal
Journal:  Biochim Biophys Acta       Date:  2003-07-11

9.  Anti-HIV-1 activity of enfuvirtide (T-20) by inhibition of bystander cell death.

Authors:  Jordi Barretina; Julià Blanco; Mercedes Armand-Ugón; Arantxa Gutiérrez; Bonaventura Clotet; José A Esté
Journal:  Antivir Ther       Date:  2003-04

10.  High level of coreceptor-independent HIV transfer induced by contacts between primary CD4 T cells.

Authors:  Julià Blanco; Berta Bosch; María Teresa Fernández-Figueras; Jordi Barretina; Bonaventura Clotet; José A Esté
Journal:  J Biol Chem       Date:  2004-09-13       Impact factor: 5.157
View more
  5 in total

1.  ADS-J1 inhibits HIV-1 entry by interacting with gp120 and does not block fusion-active gp41 core formation.

Authors:  Emmanuel González-Ortega; Maria-Pau Mena; Marc Permanyer; Ester Ballana; Bonaventura Clotet; José A Esté
Journal:  Antimicrob Agents Chemother       Date:  2010-07-19       Impact factor: 5.191

Review 2.  Novel targets for antiretroviral therapy: clinical progress to date.

Authors:  Birgitt Dau; Mark Holodniy
Journal:  Drugs       Date:  2009       Impact factor: 9.546

3.  Inhibition of coreceptor-independent cell-to-cell human immunodeficiency virus type 1 transmission by a CD4-immunoglobulin G2 fusion protein.

Authors:  Berta Bosch; Julià Blanco; Eduardo Pauls; Imma Clotet-Codina; Mercedes Armand-Ugón; Boyan Grigorov; Delphine Muriaux; Bonaventura Clotet; Jean-Luc Darlix; José A Esté
Journal:  Antimicrob Agents Chemother       Date:  2005-10       Impact factor: 5.191

4.  Identification of low-molecular weight inhibitors of HIV-1 reverse transcriptase using a cell-based high-throughput screening system.

Authors:  Oyebisi Jegede; Ana Khodyakova; Mikhail Chernov; Jan Weber; Luis Menéndez-Arias; Andrei Gudkov; Miguel E Quiñones-Mateu
Journal:  Antiviral Res       Date:  2011-05-12       Impact factor: 5.970

5.  Design of Small Molecules with HIV Fusion Inhibitory Property Based on Gp41 Interaction Assay.

Authors:  Soroush Sardari; Kayhan Azadmanesh; Fereidoun Mahboudi; Asghar Davood; Ruhollah Vahabpour; Rezvan Zabihollahi; Hosna Gomari
Journal:  Avicenna J Med Biotechnol       Date:  2013-04
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.